In Pursuit Of Greener Pastures, Roche Looks Toward China, Away From Europe
This article was originally published in PharmAsia News
In contrast to Europe, China sees the life sciences industry as an engine of innovation, not a cost factor, Roche CEO Severin Schwan says.
You may also be interested in...
Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 2 of 2)
Joe McCracken, global head of business development & licensing for Roche AG, has a unique perspective on dealmaking, filtered through the lens of a career that has spanned from biotech to Big Pharma, from the U.S. West Coast to Japan to Nutley, New Jersey.
When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.